Actively Recruiting
Development of a New Rapid Diagnostic Test to Support Onchocerciasis Elimination
Led by Bioaster · Updated on 2025-03-07
400
Participants Needed
1
Research Sites
85 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Onchocerciasis, also known as river blindness, is one of the disease targeted for elimination by the World Health Organization (WHO) in the group of Neglected Tropical Diseases. Existing diagnostic tools for onchocerciasis have limitations that make mapping, epidemiological assessments and verification of elimination of onchocerciasis difficult. It is in this context that WHO, in its 2021-2030 roadmap for onchocerciasis, has identified the development of new diagnostic tests, or the improvement of existing diagnostic tests, as a critical condition for achieving the goal of eliminating onchocerciasis transmission. To this end, a series of cross-sectional studies will be carried out in Cameroun over a one year period to collect and characterize biological samples for the development and evaluation of a new rapid diagnostic test for onchocerciasis. The study will target individuals aged 18 and over, mono-infected with one of the filarial species Onchocerca volvulus, Loa loa or Mansonella perstans; and non-infected. At the end of this study, data on the endemicity of onchocerciasis, loiasis and mansonellosis in the selected communities will be updated. More importantly, a new rapid diagnostic test will be developed, which can then be used to monitor the activities of onchocerciasis control programs.
CONDITIONS
Official Title
Development of a New Rapid Diagnostic Test to Support Onchocerciasis Elimination
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subjects informed of the study objectives and who have signed a consent form
- Subjects without filariasis (for control subjects)
- Subjects mono-infected with Onchocerca volvulus
- Subjects mono-infected with Loa loa
- Subjects mono-infected with Mansonella perstans or co-infected with Mansonella perstans and Loa loa
You will not qualify if you...
- Pregnant or breastfeeding women
- Subjects who have taken antihelminthic treatment less than 6 months before the inclusion date
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Higher Institute for Scientific and Medical Research
Yaoundé, Cameroon, 5797
Actively Recruiting
Research Team
M
Marie KOENIG
CONTACT
M
Marion DARNAUD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here